IP Library Granted Patent US 7,018,655
Granted Patent B2
US 7,018,655 · App. 10/101,093 · Granted Mar 28, 2006

Amphiphilic diblock, triblock and star-block copolymers and their pharmaceutical compositions

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,018,655
App. No.
10/101,093
Granted
Mar 28, 2006
Kind
B2
Abstract

This invention relates to novel amphiphilic diblock, triblock copolymers and star-shaped block copolymers comprising a biodegradable polymer covalently attached at the polymer ends, to a hydrophilic vinyl polymer, via divalent sulfur atom; to a process for producing the block polymers; to a polymerization process which comprises subjecting the monomers capable of radical polymerization to radical polymerization in the presence of a macromolecular biodegradable chain-transfer agent; and to pharmaceutical compositions comprising the block copolymers loaded with therapeutic agents.

Claims (16)

1. A therapeutic composition consisting of:

an amphiphilic diblock, triblock or star-shaped block copolymer formed by a biodegradable polymer selected from the group consisting of a polyester, a polyamide, a poly(ester-amide), a polyanhydride and combinations thereof, being covalently attached at the polymer ends to at least one hydrophilic vinyl polymer by way of a divalent sulfur atom; and

an effective amount of at least one therapeutic agent;

wherein said therapeutic composition is characterized by its ability to form a nanodispersion or micelle in aqueous media.

2. The therapeutic composition accordance with claim 1 wherein said hydrophilic vinyl polymer is at least one member selected from the group consisting of poly(N-2-hydroxypropylmethacrylamide), poly(N-vinylpyrrolidone), poly(ethylene glycol)methacrylate, poly(N-isopropyl acrylamide), polyacrylic acid, polymethacrylic acid, poly(2-aminoethylmethacrylate), poly(3-aminopropylmethacrylamide), poly(2-N,N-dimethylaminoethylmethacrylate) and copolymers thereof.

3. A therapeutic composition consisting of:

an amphiphilic diblock, triblock or star-shaped block copolymer formed by a biodegradable polymer selected from the group consisting of a polyester, a polyamide, a poly(ester-amide), a polyanhydride and combinations thereof, being covalently attached at the polymer ends to at least one hydrophilic vinyl polymer by way of a divalent sulfur atom;

and an effective amount of at least one therapeutic agent; and at least one targeting moiety conjugated to pendant functional groups in said at least one hydrophilic vinyl polymer;

wherein said therapeutic composition is characterized by its ability to form a nanodispersion or micelle in aqueous media.

4. The therapeutic composition accordance with claim 3 wherein said targeting moiety is at least one member selected from the group consisting of vitamins, sugars, antibodies, lectins, peptides and combinations thereof.

5. The therapeutic composition in accordance with claim 1 wherein:

said at least one therapeutic agent is poorly water-soluble and is at least one member selected from the group consisting of anticancer drugs, antifungal drugs, antiviral drugs, antibacterials, immunomodulators, central nervous system agents, anti-inflammatory drugs, or combinations thereof.

6. The therapeutic composition in accordance with claim 5 wherein:

said anticancer drug is at least one member selected from the group consisting of aluminium chloride phthalocyanines, doxorubicin, vinbiastine, paclitaxel, docetaxel, melphalan, teniposide, etiposide, and combinations thereof.

7. The therapeutic composition in accordance with claim 3 wherein said targeting moiety is provided in an amount effective to provide site-specific delivery of said therapeutic agent.

8. The therapeutic composition accordance with claim 1 wherein said biodegradable polyester is at least one member selected from the group consisting of hydroxyl or carboxyl end-functionalized linear and star shaped poly(ε-caprolactone), poly(L-lactide), poly(D-lactide), poly(D,L-lactide), poly(glycolic acid), poly(lactide-co-glycolide), poly(3-hydroxybutyrate) and derivatives thereof.

Assignments (5)
RELEASE OF SECURITY INTEREST Recorded Apr 25, 2024
From: WILMINGTON TRUST, NATIONAL ASSOCIATION
To: ENDO GLOBAL AESTHETICS LIMITED; ENDO GLOBAL VENTURES; ENDO VENTURES BERMUDA LIMITED; ENDO VENTURES LIMITED; PALADIN LABS INC.
Reel/Frame 067221/0958 →
RELEASE OF SECURITY INTEREST Recorded Apr 24, 2024
From: WILMINGTON TRUST, NATIONAL ASSOCIATION
To: ENDO GLOBAL AESTHETICS LIMITED; ENDO GLOBAL VENTURES; ENDO VENTURES BERMUDA LIMITED; ENDO VENTURES LIMITED; PALADIN LABS INC.
Reel/Frame 067216/0376 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 23, 2024
From: PALADIN LABS INC.
To: PALADIN PHARMA INC.
Reel/Frame 067203/0281 →
CONFIRMATORY GRANT OF SECURITY INTEREST IN UNITED STATES PATENTS Recorded Sep 17, 2021
From: ENDO VENTURES LIMITED; ENDO GLOBAL VENTURES; PALADIN LABS INC.
To: WILMINGTON TRUST, NATIONAL ASSOCIATION
Reel/Frame 057538/0893 →
CONFIRMATORY GRANT OF SECURITY INTEREST IN UNITED STATES PATENTS Recorded May 26, 2020
From: ENDO GLOBAL VENTURES; ENDO VENTURES LIMITED; PALADIN LABS INC.
To: WILMINGTON TRUST, NATIONAL ASSOCIATION
Reel/Frame 053548/0239 →